I spent weeks researching the triple G agonist data before pulling the trigger, mainly watching for heart rate elevation concerns. Started conservatively at 1.5mg for weeks 1–4. Waking resting heart rate only climbed 3 bpm before stabilizing. The lyophilized puck had full vacuum integrity and dissolved perfectly clear. Lipid panel and fasting glucose markers have already trended favorably on mid-cycle bloodwork. Appreciate the fast domestic shipping within Canada—order arrived in discreet, insulated packaging in 48 hours.
Priya S. (Verified Buyer)
Break through weight loss plateaus with Retatrutide (LY3437943). As an advanced triple agonist, Retatrutide accelerates energy expenditure and silences persistent food noise. In addition, it supports metabolic balance and glycemic control.
Shatter Metabolic Plateaus and Maximize Fat Loss with Retatrutide
Persistent food cravings and metabolic slowdown make fat loss difficult. When standard incretins stop delivering results, Retatrutide provides a powerful solution. Specifically, this triple agonist activates GLP-1, GIP, and glucagon receptors at the same time. Consequently, it calms appetite and elevates resting energy expenditure to break through stubborn ceilings.
Key Benefits
- Synergistic Triple Agonism: Engages three metabolic pathways simultaneously, producing superior fat loss results compared to single-target compounds.
- Accelerated Caloric Burn: Glucagon receptor activation increases hepatic energy expenditure, burning stored lipids more efficiently.
- Silences “Food Noise”: Dual incretin action calms central hunger signals, making smaller meals satisfying and reducing cravings.
- Metabolic Support: Significantly improves insulin sensitivity and reduces hepatic liver fat accumulation.
Why Choose Standard Research Labs Retatrutide?
- Accessible pricing for your research budget
- Canadian-owned and operated
- Fast domestic dispatch
- Secure, discreet packaging
Research & References
Retatrutide Guide: GIP/GLP-1/Glucagon Action, Dosing & Trial Evidence
- Application
- Research compound
- Storage
- Store lyophilized material desiccated at -20°C for long-term stability. Protect from heat and light.
- Appearance
- Lyophilized powder
- Available Sizes
- 10 mg and 20 mg
- Testing
- Independent third-party analytical testing with batch-specific COA
- Research Use
- For laboratory research use only. Not for human consumption.
- Vial Size
- 10mg, 20mg, 5mg
Retatrutide research applications include gLP-1, GIP and glucagon receptor signaling, appetite-related endpoints, glucose regulation, body-weight research.
For laboratory research use only. Not for human or animal diagnostic, clinical, or therapeutic use.
Certificate of Analysis
This certificate was issued by the laboratory shown on the report to our supplier and covers the same production lot we received. The batch code on your vial is our own tracking number for that lot, which is why it does not appear on the certificate. Standard Labs does not currently commission its own testing.
Ran this during the final 8 weeks of a contest cut. Titrated slowly from 2mg up to 4mg weekly. What makes this compound special is that you can still hit your protein target—on Sema I couldn't stomach food, which wrecked my lean mass. With Reta, food noise is gone, metabolic rate feels noticeably elevated (resting body temp stayed high), and I retained all my training strength on low carbs. Top tier batch.
Tyler B. (Verified Buyer)Switched to this after stalling on Tirz for four months and dealing with awful lethargy on injection days. The difference with Reta is unreal—the glucagon mechanism makes a massive difference in daily energy levels. Appetite suppression is smooth and quiet without that nauseous, brick-in-the-stomach feeling. Down 11 lbs in 6 weeks while eating at a slight deficit, and I actually have the energy to complete my workouts. Reconstituted with 2ml BAC water smoothly with no PIP. Won't be going back to older GLPs
Sarah G. (Verified Buyer)Write a review
Your email will not be published. Reviews may need approval before appearing.



